196 related articles for article (PubMed ID: 30537492)
21. Toll-like receptor 2 and Toll-like receptor 4 predict favorable prognosis in local pancreatic cancer.
Lanki MA; Seppänen HE; Mustonen HK; Böckelman C; Juuti AT; Hagström JK; Haglund CH
Tumour Biol; 2018 Sep; 40(9):1010428318801188. PubMed ID: 30246618
[TBL] [Abstract][Full Text] [Related]
22. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Fermér C; Nilsson O; Seppänen H; Haglund C
PLoS One; 2015; 10(6):e0129012. PubMed ID: 26053486
[TBL] [Abstract][Full Text] [Related]
23. Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma.
Tsutsumi K; Sato N; Tanabe R; Mizumoto K; Morimatsu K; Kayashima T; Fujita H; Ohuchida K; Ohtsuka T; Takahata S; Nakamura M; Tanaka M
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S491-9. PubMed ID: 21837532
[TBL] [Abstract][Full Text] [Related]
24. Expression and Prognostic Value of Small Mothers Against Decapentaplegic 7, Matrix Metalloproteinase 2, and Matrix Metalloproteinase 9 in Resectable Pancreatic Ductal Adenocarcinoma.
Zhou L; Lu J; Liang ZY; Zhou WX; Wang YZ; Jiang BL; You L; Guo JC
Pancreas; 2021 Sep; 50(8):1195-1201. PubMed ID: 34714284
[TBL] [Abstract][Full Text] [Related]
25. High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Song Y; Tang MY; Chen W; Wang Z; Wang SL
Dis Markers; 2020; 2020():7656031. PubMed ID: 33029256
[TBL] [Abstract][Full Text] [Related]
26. High expression of interleukin-22 and its receptor predicts poor prognosis in pancreatic ductal adenocarcinoma.
Wen Z; Liao Q; Zhao J; Hu Y; You L; Lu Z; Jia C; Wei Y; Zhao Y
Ann Surg Oncol; 2014 Jan; 21(1):125-32. PubMed ID: 24132627
[TBL] [Abstract][Full Text] [Related]
27. High expression of GRK3 is associated with favorable prognosis in pancreatic ductal adenocarcinoma.
Liu WJ; Zhou L; Liang ZY; Zhou WX; You L; Zhang TP; Zhao YP
Pathol Res Pract; 2018 Feb; 214(2):228-232. PubMed ID: 29254792
[TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of Ki-67 proliferative index in resectable pancreatic ductal adenocarcinoma.
Pergolini I; Crippa S; Pagnanelli M; Belfiori G; Pucci A; Partelli S; Rubini C; Castelli P; Zamboni G; Falconi M
BJS Open; 2019 Oct; 3(5):646-655. PubMed ID: 31592095
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Impact of Cell Division Cycle Associated 2 Expression on Pancreatic Ductal Adenocarcinoma.
Wang MY; Niu ZY; Gao XG; Zhou L; Liao Q; Zhao YP
Chin Med Sci J; 2016 Sep; 31(3):149-154. PubMed ID: 27733221
[TBL] [Abstract][Full Text] [Related]
30. AHNAK2 is a potential prognostic biomarker in patients with PDAC.
Lu D; Wang J; Shi X; Yue B; Hao J
Oncotarget; 2017 May; 8(19):31775-31784. PubMed ID: 28423668
[TBL] [Abstract][Full Text] [Related]
31. L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma.
Tsutsumi S; Morohashi S; Kudo Y; Akasaka H; Ogasawara H; Ono M; Takasugi K; Ishido K; Hakamada K; Kijima H
J Surg Oncol; 2011 Jun; 103(7):669-73. PubMed ID: 21360711
[TBL] [Abstract][Full Text] [Related]
32. Filamin associates with stress signalling kinases MKK7 and MKK4 and regulates JNK activation.
Nakagawa K; Sugahara M; Yamasaki T; Kajiho H; Takahashi S; Hirayama J; Minami Y; Ohta Y; Watanabe T; Hata Y; Katada T; Nishina H
Biochem J; 2010 Mar; 427(2):237-45. PubMed ID: 20156194
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma.
Liu WJ; Zhou L; Liang ZY; Zhou WX; You L; Zhang TP; Zhao YP
Chin Med J (Engl); 2018 Dec; 131(24):2947-2952. PubMed ID: 30539907
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of XB130 expression in surgically resected pancreatic ductal adenocarcinoma.
Zhang J; Jiang X; Zhang J
World J Surg Oncol; 2014 Mar; 12():49. PubMed ID: 24581082
[TBL] [Abstract][Full Text] [Related]
35. Identification of ANXA1 as a lymphatic metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma.
Liu QH; Shi ML; Bai J; Zheng JN
Asian Pac J Cancer Prev; 2015; 16(7):2719-24. PubMed ID: 25854353
[TBL] [Abstract][Full Text] [Related]
36. Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients.
Martinez-Useros J; Li W; Georgiev-Hristov T; Fernandez-Aceñero MJ; Borrero-Palacios A; Perez N; Celdran A; Garcia-Foncillas J
Pathol Oncol Res; 2019 Jan; 25(1):269-278. PubMed ID: 29101736
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of Tbx3 predicts poor prognosis of patients with resectable pancreatic carcinoma.
Wang HC; Meng QC; Shan ZZ; Yuan Z; Huang XY
Asian Pac J Cancer Prev; 2015; 16(4):1397-401. PubMed ID: 25743805
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of autophagy-related protein expression in resected pancreatic ductal adenocarcinoma.
Ko YH; Cho YS; Won HS; Jeon EK; An HJ; Hong SU; Park JH; Lee MA
Pancreas; 2013 Jul; 42(5):829-35. PubMed ID: 23429496
[TBL] [Abstract][Full Text] [Related]
39. Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma.
Pozios I; Knösel T; Zhao Y; Assmann G; Pozios I; Müller MH; Bruns CJ; Kreis ME; Seeliger H
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1887-1897. PubMed ID: 30046904
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
